Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
On efficacy, at least, BeOne’s BTK degrader shows an edge.
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
Relapsed data are uncompetitive, but the front-line PACC-mutant space offers hope.
The upcoming Rasolute-304 trial will compare daraxonrasib versus observation.
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
The company’s AN9025 will shortly enter phase 1.
